TY - JOUR T1 - Emergence of N antigen SARS-CoV-2 genetic variants escaping detection of antigenic tests JF - medRxiv DO - 10.1101/2021.03.25.21253802 SP - 2021.03.25.21253802 AU - Claudia Del Vecchio AU - Giuseppina Brancaccio AU - Alessandra Rosalba Brazzale AU - Enrico Lavezzo AU - Francesco Onelia AU - Elisa Franchin AU - Laura Manuto AU - Federico Bianca AU - Vito Cianci AU - Annamaria Cattelan AU - Stefano Toppo AU - Andrea Crisanti Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21253802.abstract N2 - SARS-CoV-2 genetic variants are emerging as a major threat to vaccination efforts worldwide as they may increase virus transmission rate and/or confer the ability to escape vaccine induced immunity with knock on effects on the level of herd immunity and vaccine efficacy respectively. These variants concern the Spike protein, which is encoded by the S gene, involved in virus entry into host cells and the major target of vaccine development. We report here that genetic variants of the N gene can impair our ability to utilize antigenic tests for both diagnosis and mass testing efforts aimed at controlling virus transmission. While conducting a large validation study on the Abbott Panbio™ COVID-19 Ag test, we noticed that some swab samples failed to generate a positive result in spite of a high viral load in Rt-PCR assays. Sequencing analysis of viruses showing discordant results in the RT-PCR and antigen assays revealed the presence of multiple disruptive amino-acid substitutions in the N antigen (the viral protein detected in the antigen test) clustered from position 229 to 374 a region known to contain an immunodominant epitope. A relevant fraction of the variants, undetected by the antigen test, contained the mutations A376T coupled to M241I. Intriguingly we found that virus sequences with this mutation were over-represented in the antigen-test-negative and PCR-positive samples and progressively increased in frequency over time in Veneto, a region of Italy that has aggressively scaled up the utilization of antigen tests, which reached nearly 68% of all the SARS-CoV-2 swab assays performed there. We speculate that mass utilization of antigen assays could create a selection pressure on the target that may favor the spread of undetectable virus variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOVID-19 emergency fund from University of Padova (grant number: TOPP_PRIV20_01)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is a retrospective diagnostic analysis. Patient consent for diagnostic investigation was taken at the time of admission. The purpose and design of the study has been approved by the Local Ethics Committee of the Province of Padova (Italy) which has acknowledged to be in line with ethical practices and ICH-CGP guidelines. (protocol number 69295; date 18/11/2020 Approval obtained 17/12/2020 with Protocol number 0001609, 13/1/2021) All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available as supplementary material ER -